NMRA officer 10b5-1 sale: 114,703 shares at $2.6767

Q: What insider transaction did NMRA report?

Daljit Singh Aurora sold 114,703 shares of Neumora Therapeutics common stock on 11/11/2025.

Q: At what price were the NMRA shares sold?

The sale was executed at a weighted average price of $2.6767, with trades ranging from $2.65 to $2.81.

Q: Was the NMRA insider sale under a 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1 trading plan adopted on April 22, 2024.

Q: How many NMRA shares does the insider hold after the sale?

After the transaction, Aurora reported 88,935 shares held directly and 0 shares held indirectly.

Q: Who held the NMRA shares that were sold?

The sold shares were held by the Aurora Family Trust.

Q: What is Daljit Singh Aurora’s role at NMRA?

He is the company’s Chief Operating and Development Officer.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Neumora Therapeutics (NMRA) officer Daljit Singh Aurora reported an open-market sale of 114,703 shares of common stock on 11/11/2025 at a weighted average price of $2.6767. The sale was made under a Rule 10b5-1 trading plan adopted on April 22, 2024, and the sold shares were held by the Aurora Family Trust. Following the transaction, Aurora reported 88,935 shares held directly and 0 shares held indirectly.

Insider Trade Summary

Net Seller: 114,703 shares

Net Sell 2 txns

Insider Aurora Daljit Singh

Role See Remarks

Sold 114,703 shs ($307K)

Type	Security	Shares	Price	Value
Sale	Common Stock	114,703	$2.6767	$307K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Indirect, See footnote); Common Stock — 88,935 shares (Direct)

Footnotes (3)

F1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 22, 2024.
F2. This transaction was executed in multiple trades in prices ranging from $2.65 to $2.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3. Shares held by Aurora Family Trust.

FAQ

What insider transaction did NMRA report?

Daljit Singh Aurora sold 114,703 shares of Neumora Therapeutics common stock on 11/11/2025.

At what price were the NMRA shares sold?

The sale was executed at a weighted average price of $2.6767, with trades ranging from $2.65 to $2.81.

Was the NMRA insider sale under a 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1 trading plan adopted on April 22, 2024.

How many NMRA shares does the insider hold after the sale?

After the transaction, Aurora reported 88,935 shares held directly and 0 shares held indirectly.

Who held the NMRA shares that were sold?

The sold shares were held by the Aurora Family Trust.

What is Daljit Singh Aurora’s role at NMRA?

He is the company’s Chief Operating and Development Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/13/2025 - 04:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aurora Daljit Singh

(Last)

(First)

(Middle)

C/O NEUMORA THERAPEUTICS, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN

02472

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/11/2025		S⁽¹⁾		114,703	D	$2.6767⁽²⁾	0	I	See footnote⁽³⁾
Common Stock								88,935	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 22, 2024.

2. This transaction was executed in multiple trades in prices ranging from $2.65 to $2.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Shares held by Aurora Family Trust.

Remarks:

Title: Chief Operating and Development Officer

	/s/ Michael Milligan, as Attorney-in-Fact for Daljit Singh Aurora	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR